SCOR Global Life has made a strategic investment in BioSerenity, a French medical solutions company that aims to optimize the patient pathways in several chronic diseases through the design of connected devices, end-t
This publication presents some global information on kidney diseases, the definitions and basic notions, protective treatments, renal replacement therapies, disease progression information as well as proposed underwri
A weather analysis of China’s agricultural production risk
In order to achieve the objectives of the “Quantum Leap” strategic plan, SCOR Global Life evolves its organisation and announces promotions in its Global Markets team.
First Nine Months 2019 Results
SCOR delivers a solid performance with net income of EUR 401 million in the first nine months of 2019
